Cargando…

Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients

PURPOSE: Double heterozygosity (DH) for BRCA1 and BRCA2 variant is very rare with only a few cases reported, and most those in Caucasians. In this article, we present seven unrelated cases of DH for BRCA1/2 identified from a single institution in Korea, and describe the characteristics and phenotype...

Descripción completa

Detalles Bibliográficos
Autores principales: Bang, Yoon Ju, Kwon, Won Kyung, Nam, Seok Jin, Kim, Seok Won, Chae, Byung-Joo, Lee, Se Kyung, Ryu, Jai Min, Kim, Jong-Won, Yu, Jonghan, Lee, Jeong Eon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296941/
https://www.ncbi.nlm.nih.gov/pubmed/34645131
http://dx.doi.org/10.4143/crt.2021.791
_version_ 1784750373410439168
author Bang, Yoon Ju
Kwon, Won Kyung
Nam, Seok Jin
Kim, Seok Won
Chae, Byung-Joo
Lee, Se Kyung
Ryu, Jai Min
Kim, Jong-Won
Yu, Jonghan
Lee, Jeong Eon
author_facet Bang, Yoon Ju
Kwon, Won Kyung
Nam, Seok Jin
Kim, Seok Won
Chae, Byung-Joo
Lee, Se Kyung
Ryu, Jai Min
Kim, Jong-Won
Yu, Jonghan
Lee, Jeong Eon
author_sort Bang, Yoon Ju
collection PubMed
description PURPOSE: Double heterozygosity (DH) for BRCA1 and BRCA2 variant is very rare with only a few cases reported, and most those in Caucasians. In this article, we present seven unrelated cases of DH for BRCA1/2 identified from a single institution in Korea, and describe the characteristics and phenotype of DH individuals compared to those with a single BRCA variant. MATERIALS AND METHODS: This study included 27,678 patients diagnosed with breast cancer and surgically treated at Samsung Medical Center (SMC) between January 2008 and June 2020. In total, 4,215 high-risk breast cancer patients were tested for the BRCA1/2 genes, and electronic medical records from 456 cases with pathogenic/likely pathogenic variants were reviewed. RESULTS: A younger mean age at diagnosis was associated with DH than a single variant of BRCA1/2. More triple-negative breast cancer and higher nuclear and histologic grade cancer occurred with DH than BRCA2 variant. All seven cases of DH were unrelated, and their mutation combinations were different. There were no Ashkenazi founder variants detected. CONCLUSION: We suggest that patients with DH for BRCA1/2 variants develop breast cancer at a younger age, but the histopathologic features are similar to those of BRCA1.
format Online
Article
Text
id pubmed-9296941
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-92969412022-07-20 Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients Bang, Yoon Ju Kwon, Won Kyung Nam, Seok Jin Kim, Seok Won Chae, Byung-Joo Lee, Se Kyung Ryu, Jai Min Kim, Jong-Won Yu, Jonghan Lee, Jeong Eon Cancer Res Treat Original Article PURPOSE: Double heterozygosity (DH) for BRCA1 and BRCA2 variant is very rare with only a few cases reported, and most those in Caucasians. In this article, we present seven unrelated cases of DH for BRCA1/2 identified from a single institution in Korea, and describe the characteristics and phenotype of DH individuals compared to those with a single BRCA variant. MATERIALS AND METHODS: This study included 27,678 patients diagnosed with breast cancer and surgically treated at Samsung Medical Center (SMC) between January 2008 and June 2020. In total, 4,215 high-risk breast cancer patients were tested for the BRCA1/2 genes, and electronic medical records from 456 cases with pathogenic/likely pathogenic variants were reviewed. RESULTS: A younger mean age at diagnosis was associated with DH than a single variant of BRCA1/2. More triple-negative breast cancer and higher nuclear and histologic grade cancer occurred with DH than BRCA2 variant. All seven cases of DH were unrelated, and their mutation combinations were different. There were no Ashkenazi founder variants detected. CONCLUSION: We suggest that patients with DH for BRCA1/2 variants develop breast cancer at a younger age, but the histopathologic features are similar to those of BRCA1. Korean Cancer Association 2022-07 2021-10-13 /pmc/articles/PMC9296941/ /pubmed/34645131 http://dx.doi.org/10.4143/crt.2021.791 Text en Copyright © 2022 by the Korean Cancer Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Bang, Yoon Ju
Kwon, Won Kyung
Nam, Seok Jin
Kim, Seok Won
Chae, Byung-Joo
Lee, Se Kyung
Ryu, Jai Min
Kim, Jong-Won
Yu, Jonghan
Lee, Jeong Eon
Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients
title Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients
title_full Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients
title_fullStr Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients
title_full_unstemmed Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients
title_short Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients
title_sort clinicopathological characterization of double heterozygosity for brca1 and brca2 variants in korean breast cancer patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296941/
https://www.ncbi.nlm.nih.gov/pubmed/34645131
http://dx.doi.org/10.4143/crt.2021.791
work_keys_str_mv AT bangyoonju clinicopathologicalcharacterizationofdoubleheterozygosityforbrca1andbrca2variantsinkoreanbreastcancerpatients
AT kwonwonkyung clinicopathologicalcharacterizationofdoubleheterozygosityforbrca1andbrca2variantsinkoreanbreastcancerpatients
AT namseokjin clinicopathologicalcharacterizationofdoubleheterozygosityforbrca1andbrca2variantsinkoreanbreastcancerpatients
AT kimseokwon clinicopathologicalcharacterizationofdoubleheterozygosityforbrca1andbrca2variantsinkoreanbreastcancerpatients
AT chaebyungjoo clinicopathologicalcharacterizationofdoubleheterozygosityforbrca1andbrca2variantsinkoreanbreastcancerpatients
AT leesekyung clinicopathologicalcharacterizationofdoubleheterozygosityforbrca1andbrca2variantsinkoreanbreastcancerpatients
AT ryujaimin clinicopathologicalcharacterizationofdoubleheterozygosityforbrca1andbrca2variantsinkoreanbreastcancerpatients
AT kimjongwon clinicopathologicalcharacterizationofdoubleheterozygosityforbrca1andbrca2variantsinkoreanbreastcancerpatients
AT yujonghan clinicopathologicalcharacterizationofdoubleheterozygosityforbrca1andbrca2variantsinkoreanbreastcancerpatients
AT leejeongeon clinicopathologicalcharacterizationofdoubleheterozygosityforbrca1andbrca2variantsinkoreanbreastcancerpatients